FirsthandHealth
medRxiv PreprintsInternational10 November 2026

Saccharomyces boulardii as Adjunctive Therapy in Helicobacter pylori Eradication: A Randomized, Placebo-Controlled Trial.

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Abstract Background: Helicobacter pylori (H. pylori) infection remains highly prevalent in Iran, where high antibiotic resistance can limit eradication efficacy. Saccharomyces boulardii (S. boulardii) may improve eradication and treatment tolerability, although evidence remains inconsistent. This trial evaluated adjunctive S. boulardii in a high-prevalence, high-resistance setting. Methods: In this randomized, single-blind, placebo-controlled trial, 218 H. pylori-positive adults received 14 days of PPI, bismuth, amoxicillin, and clarithromycin (P-BAC) plus either S. boulardii (250 mg twice dai
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.